ArticleIrish journal of medical science2026
A predictive nomogram for relapse risk in children with autoimmune encephalitis.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAutoimmune encephalitis (AE) is a major cause of acute encephalopathy in children, and relapse is strongly linked to long-term neurodevelopmental sequelae. However, studies on relapse risk prediction in the Chinese pediatric population remain limited, and validated tools for individualized risk stratification are lacking. This study aimed to develop and validate a nomogram for predicting relapse risk in children with AE.
methodsThis retrospective cohort study included 127 children aged 1-16 years diagnosed with AE at a tertiary pediatric center in China between 2017 and 2023. Independent predictors of relapse were identified using univariable and multivariable logistic regression. A nomogram was constructed and comprehensively validated for discrimination, calibration, and stability.
resultsThe overall relapse rate was 26.8% (34/127). Independent risk factors for relapse included age ≥ 8 years at onset (OR 3.19, 95% CI 1.37-7.42, P 0.007), limb weakness (OR 2.36, 95% CI 1.03-5.42, P 0.041), delayed immunotherapy (OR 2.77, 95% CI 1.23-6.24, P 0.013), and positive N-methyl-D-aspartate receptor (NMDAR) antibody (OR 2.91, 95% CI 1.29-6.56, P 0.010). Rituximab treatment (OR 0.43, 95%CI 0.19-0.95, P 0.036) and IVIG treatment ≥ 6 months (OR 0.35, 95%CI 0.13-0.92, P 0.033) were confirmed as independent protective factors. The nomogram showed excellent discriminative ability (C-statistic 0.936, R² 0.683), good calibration (Brier score 0.081, calibration intercept < 0.001, slope 1.000), and robust stability on internal validation with 1000 bootstrap resamples.
conclusionThis nomogram demonstrates favorable accuracy and clinical utility for individualized relapse risk prediction in Chinese children with AE.
Indexed as
Identifiers
42412135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.